Eileen Regan

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
    Jennifer A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Cancer Chemother Pharmacol 71:1241-6. 2013
  2. ncbi request reprint Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors
    Jennifer A Chan
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 30:2963-8. 2012
  3. pmc A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
    J A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 22:1367-73. 2011
  4. ncbi request reprint Hormone replacement therapy and survival after colorectal cancer diagnosis
    Jennifer A Chan
    Dana Farber Cancer Institute, Dana 1220, Boston, MA 02115, USA
    J Clin Oncol 24:5680-6. 2006
  5. ncbi request reprint Emerging therapies for the treatment of patients with advanced neuroendocrine tumors
    Jennifer A Chan
    Dana Farber Cancer Institute, Department of Medical Oncology, 44 Binney Street, Boston, MA 02115, USA
    Expert Opin Emerg Drugs 12:253-70. 2007
  6. pmc Association of family history with cancer recurrence and survival among patients with stage III colon cancer
    Jennifer A Chan
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 299:2515-23. 2008
  7. pmc Progress in the treatment of neuroendocrine tumors
    Jennifer A Chan
    Gastrointestinal Cancer Center, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Curr Oncol Rep 11:193-9. 2009
  8. pmc Phase II study of pemetrexed in patients with advanced neuroendocrine tumors
    Jennifer A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, Dana 1220, Boston, MA, 02115, USA
    Cancer Chemother Pharmacol 66:961-8. 2010
  9. doi request reprint New treatment options for patients with advanced neuroendocrine tumors
    Jennifer A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Curr Treat Options Oncol 12:136-48. 2011
  10. doi request reprint A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor
    Jennifer A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts
    Cancer 119:3212-8. 2013

Collaborators

Detail Information

Publications15

  1. pmc Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
    Jennifer A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Cancer Chemother Pharmacol 71:1241-6. 2013
    ..Because of potential synergy between VEGF pathway and mTOR inhibitors, we performed a phase I study to evaluate the safety and feasibility of combining sorafenib and everolimus in patients with advanced NET...
  2. ncbi request reprint Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors
    Jennifer A Chan
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 30:2963-8. 2012
    ..We performed a phase II study to evaluate the efficacy of temozolomide in combination with bevacizumab in patients with locally advanced or metastatic NETs...
  3. pmc A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
    J A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 22:1367-73. 2011
    ..We carried out a multi-institutional phase II study of cetuximab, a monoclonal antibody against EGFR, in patients with unresectable or metastatic esophageal or gastric adenocarcinoma...
  4. ncbi request reprint Hormone replacement therapy and survival after colorectal cancer diagnosis
    Jennifer A Chan
    Dana Farber Cancer Institute, Dana 1220, Boston, MA 02115, USA
    J Clin Oncol 24:5680-6. 2006
    ..Postmenopausal estrogen use has been shown to decrease the incidence of colorectal cancer, but there is limited information regarding the effect of estrogen use on survival after diagnosis of colorectal cancer...
  5. ncbi request reprint Emerging therapies for the treatment of patients with advanced neuroendocrine tumors
    Jennifer A Chan
    Dana Farber Cancer Institute, Department of Medical Oncology, 44 Binney Street, Boston, MA 02115, USA
    Expert Opin Emerg Drugs 12:253-70. 2007
    ..Ongoing randomized studies should help better define the role these agents will play in the future treatment of patients with this disease...
  6. pmc Association of family history with cancer recurrence and survival among patients with stage III colon cancer
    Jennifer A Chan
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 299:2515-23. 2008
    ..However, the influence of family history on cancer recurrence and survival among patients with established disease remains uncertain...
  7. pmc Progress in the treatment of neuroendocrine tumors
    Jennifer A Chan
    Gastrointestinal Cancer Center, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Curr Oncol Rep 11:193-9. 2009
    ..Additionally, agents targeting the vascular endothelial growth factor pathway and mammalian target of rapamycin have shown preliminary evidence of activity and are currently being evaluated in large randomized studies...
  8. pmc Phase II study of pemetrexed in patients with advanced neuroendocrine tumors
    Jennifer A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, Dana 1220, Boston, MA, 02115, USA
    Cancer Chemother Pharmacol 66:961-8. 2010
    ..Pemetrexed is a multitargeted antifolate with activity in tumor types not significantly responsive to other antifolates. We evaluated the efficacy of pemetrexed in a phase II study of patients with advanced neuroendocrine tumors...
  9. doi request reprint New treatment options for patients with advanced neuroendocrine tumors
    Jennifer A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Curr Treat Options Oncol 12:136-48. 2011
    ..Future studies will likely further define the role of these agents in the advanced carcinoid patient population...
  10. doi request reprint A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor
    Jennifer A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts
    Cancer 119:3212-8. 2013
    ..A phase 1/2 study was performed to evaluate the safety and efficacy of temozolomide in combination with everolimus in patients who have advanced pancreatic NET...
  11. pmc A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 68:293-300. 2011
    ..We performed a prospective, phase II study of 2ME2, administered in combination with bevacizumab, in patients with advanced carcinoid tumors...
  12. pmc Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Oncologist 18:377-8. 2013
    ..We evaluated tolerability and efficacy of tivozanib (an oral VEGF receptor-1, -2, -3 inhibitor) plus everolimus (an oral mammalian target of rapamycin inhibitor)...
  13. pmc Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 7:e38231. 2012
    ..To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer...
  14. ncbi request reprint Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer
    Andrew X Zhu
    Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 59:285-93. 2007
    ....
  15. pmc Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 19:1557-66. 2013
    ..We conducted a single-arm phase II study of cediranib, a pan-VEGFR tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC)...